The announcement hints at BTX1204 being a potential blockbuster:
"....Phase 1b patient study results suggests that BTX 1204 potentially has a broader mechanism of action than Eucrisa®, with substantial reduction in the key signs of atopic dermatitis already observed."
Considering that with the figures associated with the Pfizer's transaction in 2016, BOT looks like one of the rarest finds on the ASX (or any other stock market really) a potential 100 bags from here - and that's only for AD.
Time will tell, I'm starting my vacations early this year.
Wishing all a Merry Xmas.
The announcement hints at BTX1204 being a potential blockbuster:...
-
- There are more pages in this discussion • 194 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.020(5.97%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 36.0¢ | 33.3¢ | $2.622M | 7.530M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 106888 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 462320 | 5 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
